Yesterday, thePMPRB released its Annual Reportfor the year ending December 31, 2013. The Annual Report is an extensive document that reviews all of the PMPRB´s major activities, analyses of the prices of patented medicines and of the price trends of all drugs, and reports on the R&D expenditures as reported by ... Read More
16
Sep2014
16
Sep2014
The Canadian Agency for Drugs and Technologies in Health (CADTH) revised its Guidelines for Manufacturers on Application Fees for the Common Drug Review. A draft version was circulated for stakeholder feedback in July, following which the below key changes were made:
Fees for resubmission based on new clinical information ... Read More
18
Aug2014
The C-MAP™ Canadian Drug Benefit Plans Reference Guide is the authoritative source for comprehensive and up-to-date information on Canadian reimbursement and market access for pharmaceutical market access specialists. The publication highlights each of the relevant agencies, organizations and drug plans operating in the market access and reimbursement environment in Canada. ... Read More
06
Aug2014
Direct-Acting Antivirals for Chronic Hepatitis C Genotype 1: Draft recommendations posted, feedback requested
Yesterday the Canadian Agency for Drugs and Technologies in Health (CADTH)posted on its website the draft Canadian Drug Expert Committee (CDEC) recommendations report stemming from itsrecent therapeutic review project to assess the clinical and economic impact ... Read More
05
Aug2014
Included in this edition are:
New Board Member Appointed (Carolyn Kobernick)
Staffing Changes
Sylvie Dupont’s retirement
Guillaume Couillard joins the PMPRB (new Director of the Board Secretariat, Communications and Strategic Planning)
Appointments:
Tanya Potashnik (Director of the Policy and Economic Analysis Branch)
Elena Lungu (Manager of the National Prescription Drug Utilization Information System (NPDUIS))
Decisions in Cases: ratio-Salbutamol, ... Read More
31
Jul2014
The Canadian Agency for Drugs and Technologies in Health (CADTH) is requesting stakeholder feedback on its draft guidance document, released today, concerning its recent announcement to introduce industry application fees for manufacturer submissions and resubmissions made to the Common Drug Review.
The draft Guidelines for Manufacturers on Application Fees ... Read More
30
Jul2014
An updated table with the targeted Canadian Drug Expert Committee (CDEC) meeting dates is now available on the CADTH website
A CDEC meeting will be held in December 2014 as part of an initiative to eliminate an accumulation of CDR submissions.
CADTH is extending the pilot process for receiving patient input ... Read More
29
Jul2014
New Brunswick is the latest Canadian province to establish a specialized drug plan to fund high cost drugs for certain rare diseases. Starting August 1,2014, the planwill begin accepting applications to cover the cost of five drugs for the following specific rare diseases:
Aldurazyme for the treatment of Hurler and Hurler-Scheie ... Read More
24
Jul2014
Following the transfer of the pan-Canadian Oncology Drug Review (pCODR) to CADTH beginning in April 2014, a survey was conducted to identify stakeholder concerns regarding the transfer.
Stakeholder Information Sessions on the transfer held on June 9, 2014 were attended by patient advocacy groups, oncology professionals, pharmaceutical manufacturers, associations, and consultants. ... Read More
09
Jul2014
The Federal Government had not tabled the PMPRB 2013 Annual Report when Parliament rose on June 20th, 2014 although the report would have been submitted by the PMPRB to the Minister of Health in May 2014. There are two summer adjournment tabling dates (July 16th and August 20th) when the ... Read More